Regeneron hits new high after touting eye drug outlook
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals’ stock hit an all-time high, rising more than 7%, after the company gave a bullish outlook for its eye disease drug Eylea on the heels of a strong finish to 2013.